Overview

Price chart · mood · technical indicators

BBIO

BridgeBio Pharma Incstock Healthcare

Biotechnology

$71.1185.18%Current Market Mood:Bullish

Market Mood

Price Range (1Y)

$31.77$84.94

Current: $71.11

Idea: EMA

1Y Return

+105.2%

Sharpe 3Y

0.82

Market Comparison

vs Healthcare Sector & Biotechnology Industry

BBIO

+85.18%

1Y Performance

Fundamentals

Updated daily after market close

P/E ratio—

EPS (TTM)$-3.780.0% YoY

Profit margin-144.4%HEALTHCARE

Market cap$13.51BLarge cap

Wall Street coverage

$100.52median target· current $27.03 (+271.9%)22 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: —
PEG ratio: —
P/B: 123.68
P/S (TTM): 26.92
EV/EBITDA: -9.40

Profitability & growth

ROE (TTM): -1790.0%
Operating margin: -83.3%
Revenue growth YoY: 2521.0%
Dividend yield: —
Beta: 1.09

Last earnings

Feb 19, 2026 · Estimate $-0.72 · Reported $-0.94

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About BridgeBio Pharma Inc

Company profile

BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases. The company is headquartered in Palo Alto, California.

Classification

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: 3160 PORTER DRIVE, PALO ALTO, CA
Fiscal year end: December
Latest quarter: Dec 31, 2025

Market cap$13.51B

Shares outstanding$193.9M

52W high$84.94

52W low$31.77

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer

Overview

BBIO

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Truist Financial Keeps Their Buy Rating on BridgeBio Pharma (BBIO)

The Escalator: BridgeBio Oncology Therapeutics, Haleon, AstraZeneca and more

Why BridgeBio Pharma (BBIO) Is Down 6.4% After Attruby’s Faster-Than-Expected Commercial Ramp - And What's Next

BridgeBio Pharma Is Maintained at Buy by Truist Securities

BridgeBio earnings on deck: Can Attruby sustain rapid growth?

BBIO Maintained by Truist Securities -- Price Target Raised to $102

H.C. Wainwright reiterates BridgeBio Pharma stock rating on stable Vyndamax outlook By Investing.com

Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.

BofA raises BridgeBio Pharma stock price target on Pfizer settlement clarity

Mizuho reiterates BridgeBio Pharma stock rating on Vyndamax patent news

BridgeBio (BBIO) Shares Surge Following Pfizer Patent Settlement

BBIO Stock Draws Bulls As Rare-Disease Pipeline Gains Steam

BridgeBio seesaws after settlement in Pfizer Vyndamax patent dispute (update) (BBIO:NASDAQ)

(BPRW) BridgeBio Launches Health Education Effort on Often Overlooked Heart Condition Featuring Attruby® Advocates, Morgan Freeman and Sports Business Icon Howard H. White

Morgan Freeman joins push on a heart disease often mistaken for heart failure

BridgeBio Pharma gains as investors refocus on pipeline catalysts ahead of expected earnings

BBIO Reiterated by HC Wainwright & Co. -- Price Target Maintained at $100

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

There Are Early Signals Ahead of Tafamidis Trial As Analysts See Potential Upside for Pfizer (PFE) and BridgeBio Pharma (BIO)

A Look At BridgeBio Pharma (BBIO) Valuation After Mixed Short Term Returns And Strong Long Term Gains

About BridgeBio Pharma Inc

Classification

Company profile

BBIO

Market Comparison

BBIO Market Analysis

Overview

BBIO

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Truist Financial Keeps Their Buy Rating on BridgeBio Pharma (BBIO)

The Escalator: BridgeBio Oncology Therapeutics, Haleon, AstraZeneca and more

Why BridgeBio Pharma (BBIO) Is Down 6.4% After Attruby’s Faster-Than-Expected Commercial Ramp - And What's Next

BridgeBio Pharma Is Maintained at Buy by Truist Securities

BridgeBio earnings on deck: Can Attruby sustain rapid growth?

BBIO Maintained by Truist Securities -- Price Target Raised to $102

H.C. Wainwright reiterates BridgeBio Pharma stock rating on stable Vyndamax outlook By Investing.com

Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.

BofA raises BridgeBio Pharma stock price target on Pfizer settlement clarity

Mizuho reiterates BridgeBio Pharma stock rating on Vyndamax patent news

BridgeBio (BBIO) Shares Surge Following Pfizer Patent Settlement

BBIO Stock Draws Bulls As Rare-Disease Pipeline Gains Steam

BridgeBio seesaws after settlement in Pfizer Vyndamax patent dispute (update) (BBIO:NASDAQ)

(BPRW) BridgeBio Launches Health Education Effort on Often Overlooked Heart Condition Featuring Attruby® Advocates, Morgan Freeman and Sports Business Icon Howard H. White

Morgan Freeman joins push on a heart disease often mistaken for heart failure

BridgeBio Pharma gains as investors refocus on pipeline catalysts ahead of expected earnings

BBIO Reiterated by HC Wainwright & Co. -- Price Target Maintained at $100

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

There Are Early Signals Ahead of Tafamidis Trial As Analysts See Potential Upside for Pfizer (PFE) and BridgeBio Pharma (BIO)

A Look At BridgeBio Pharma (BBIO) Valuation After Mixed Short Term Returns And Strong Long Term Gains

About BridgeBio Pharma Inc

Classification

Company profile

BBIO

Market Comparison